Objective To provide an information reference for the construction of an intelligent management system for off-label drug use for inpatients with rheumatic and immune diseases.Methods Off-label drug use orders of inpatients with rheumatic and immune diseases in the 900th Hospital of the Chinese PLA Joint Logistic Support Force from November 2021 to October 2022 were collected,and the number and types of off-label drug use were analyzed and classified according to whether the off-label drug use has been recorded by the hospital.The evidence-based evidence data were collected and the evidence levels were classified for those that have not been recorded.The hospital's off-label drug use intelligent management system was used for managing those that have been recorded.Results A total of 256 medical records of inpatients with rheumatic and immune diseases were included,of which 214 medical records(83.59%)had off-label drug use.A total of 421 medication orders had off-label drug use,24 diseases and 17 drugs were involved.The types of off-label drug use were off-indication drug use(97.39%)and off-population drug use(2.61%).There were 120 items of off-label drug use in different rheumatic and immune diseases,of which 24 items(20.00%)had been recorded,and 96 items(80.00%)had not been recorded.Conclusion Off-label drug use for rheumatic and immune diseases is common in this hospital,but the proportion of off-label drug use content that has been recorded is relatively low.The intelligent management of off-label drug use helps to further improve the management level of the off-label drug use in the hospital.
rheumatic and immune diseaseoff-label drug useinformation system constructionevidence-based evidence
维普
万方数据
